Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
BioPharma Dive
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
pharminent
May 6, 2026 (Last updated: May 7, 2026)
BioPharma Dive
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
